High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort

Atherosclerosis

Volumn 246, Issue , 2016, Pages 229-235

  McGarrah, Robert W ^a,b   Craig, Damian M ^b   Haynes, Carol ^b   Dowdy, Z Elaine ^b   Shah, Svati H ^a,b,c   Kraus, William E ^a,b  

^a Division of Cardiology   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; HDL; HDL subclasses; Mortality; Risk prediction

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN PARTICLE CONCENTRATION; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CLASSIFICATION; DISCRIMINANT ANALYSIS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR;

AGED; BIOMARKERS; CARDIAC CATHETERIZATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84955453076     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.012     Document Type: Article

References (42)

1. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012, 367(22):2089-2099. 10.1056/NEJMoa1206797.
2. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357(21):2109-2122. 10.1056/NEJMoa0706628.
3. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365(24):2255-2267. 10.1056/NEJMoa1107579.
4. Landray M.J., Haynes R., Hopewell J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 2014, 371(3):203-212. 10.1056/NEJMoa1300955.
5. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380(9841):572-580. 10.1016/S0140-6736(12)60312-2.
6. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384(9943):618-625. 10.1016/S0140-6736(14)61217-4.
7. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60(6):508-516. 10.1016/j.jacc.2012.03.060.
8. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128(11):1189-1197. 10.1161/CIRCULATIONAHA.113.002671.
9. Parish S., Offer A., Clarke R., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF heart protection study. Circulation 2012, 125(20):2469-2478. 10.1161/CIRCULATIONAHA.111.073684.
10. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006, 113(12):1556-1563. 10.1161/CIRCULATIONAHA.105.565135.
11. Qi Y., Fan J., Liu J., et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J. Am. Coll. Cardiol. 2015, 65(4):355-363. 10.1016/j.jacc.2014.11.019.
12. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec cardiovascular study. Arterioscler. Thromb. Vasc. Biol. 1997, 17(6):1098-1105.
13. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med. 1991, 325(6):373-381. 10.1056/NEJM199108083250601.
14. Sweetnam P.M., Bolton C.H., Yarnell J.W., et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The caerphilly and speedwell collaborative heart disease studies. Circulation 1994, 90(2):769-774.
15. Yu S., Yarnell J.W.G., Sweetnam P., Bolton C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the caerphilly study. Atherosclerosis 2003, 166(2):331-338.
16. Martin S.S., Khokhar A a, May H.T., et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur. Heart J. 2014, 1-9. 10.1093/eurheartj/ehu264.
17. Shah S.H., Granger C.B., Hauser E.R., et al. Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: design of and rationale for the measurement to understand the reclassification of disease of cabarrus and Kannapolis (MURDOCK) horizon 1 cardiovascular disease. Am. Heart J. 2010, 160(3). 371-379.e2. 10.1016/j.ahj.2010.06.051.
18. Kraus W., Granger C., Sketch M., et al. A guide for cardiovascular genomics biorepository: the CATHGEN experience. J. Cardiovasc. Transl. Res. 2016, 8(8):449-457. 2015 Nov. 10.1007/s12265-015-9648-y.
19. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26(4):847-870. 10.1016/j.cll.2006.07.006.
20. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57(3):392-410. 10.1373/clinchem.2010.155333.
21. Fox K a a, Dabbous O.H., Goldberg R.J., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006, 333(7578):1091. 10.1136/bmj.38985.646481.55.
22. Fox K.A.A., Fitzgerald G., Puymirat E., et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014, 4(2):e004425. 10.1136/bmjopen-2013-004425.
23. Airan-Javia S.L., Wolf R.L., Wolfe M.L., Tadesse M., Mohler E., Reilly M.P. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am. Heart J. 2009, 157(4). 687.e1-8. 10.1016/j.ahj.2009.01.001.
24. Jafri H., Alsheikh-Ali A a, Mooney P., Kimmelstiel C.D., Karas R.H., Kuvin J.T. Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J. Clin. Lipidol. 2009, 3(1):45-50. 10.1016/j.jacl.2008.12.003.
25. Nicholls S.J., Brewer H.B., Kastelein J.J.P., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306(19):2099-2109. 10.1001/jama.2011.1649.
26. Kastelein J.J.P., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 2007, 356(16):1620-1630. 10.1056/NEJMoa071359.
27. Rizzo M., Otvos J.D., Nikolic D., Montalto G., Toth P.P., Banach M. Subfractions and subpopulations of HDL: an update. Curr. Med. Chem. 2014, 21(1):1-11.
28. Martin S.S., Jones S.R., Toth P.P. High-density lipoprotein subfractions: current views and clinical practice applications. Trends Endocrinol. Metab. 2014, 25(7):329-336. 10.1016/j.tem.2014.05.005.
29. Tiozzo E., Gardener H., Hudson B.I., et al. High-density lipoprotein subfractions and carotid plaque: the northern Manhattan Study. Atherosclerosis 2014, 237(1):163-168. 10.1016/j.atherosclerosis.2014.09.002.
30. Kim D.S., Burt A.A., Rosenthal E.A., et al. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J. Am. Heart Assoc. 2014, 3(3):e000902. 10.1161/JAHA.114.000902.
31. Mora S., Caulfield M.P., Wohlgemuth J., et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the JUPITER trial. Circulation 2015, 10.1161/CIRCULATIONAHA.115.016857.
32. Calabresi L., Gomaraschi M., Simonelli S., Bernini F., Franceschini G. HDL and atherosclerosis: insights from inherited HDL disorders. Biochim. Biophys. Acta 2014, 10.1016/j.bbalip.2014.07.015.
33. Du X., Kim M.-J., Hou L., et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ. Res. 2015, 116(7):1133-1142. 10.1161/CIRCRESAHA.116.305485.
34. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 2011, 17(10):594-603. 10.1016/j.molmed.2011.05.013.
35. Mackey R.H., Mora S., Bertoni A.G., et al. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care 2015, 38(4):628-636. 10.2337/dc14-0645.
36. El Harchaoui K., Arsenault B.J., Franssen R., et al. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 2009, 150(2):84-93.
37. Akinkuolie A.O., Paynter N.P., Padmanabhan L., Mora S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ. Cardiovasc. Qual. Outcomes 2014, 7(1):55-63. 10.1161/CIRCOUTCOMES.113.000675.
38. Ansell B.J., Fonarow G.C., Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 2007, 18(4):427-434. 10.1097/MOL.0b013e3282364a17.
39. HB G., Rao V.S., Kakkar V.V. Friend turns Foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol 2011, 2011:274629. 10.1155/2011/274629.
40. Van Linthout S., Frias M., Singh N., De Geest B. Therapeutic potential of HDL in cardioprotection and tissue repair. Handb. Exp. Pharmacol. 2015, 224:527-565. 10.1007/978-3-319-09665-0_17.
41. Rohatgi A., Khera A., Berry J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 2014, 141118051511004. 10.1056/NEJMoa1409065.
42. Mora S., Wenger N.K., Demicco D a, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the treating to new targets (TNT) study. Circulation 2012, 125(16):1979-1987. 10.1161/CIRCULATIONAHA.111.088591.